The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., & Koff, A. (1994) · Genes & Development · doi:10.1101/gad.8.1.9 · Cited by 1,954
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Regulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
Mitotic kinases as regulators of cell division and its checkpoints
Nigg, E. A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35048096 · Cited by 1,547
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
E2F integrates cell cycle progression with DNA repair, replication, and G 2 /M checkpoints
Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young, R. A., & Dynlacht, B. D. (2002) · Genes & Development · doi:10.1101/gad.949802 · Cited by 1,125
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
D-type cyclin-dependent kinase activity in mammalian cells.
Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., & Kato, J. Y. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2066 · Cited by 1,064
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Chu, I. M., Hengst, L., & Slingerland, J. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2347 · Cited by 990
Sherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.15.1831 · Cited by 962
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Ohshima, T., Ward, J. M., Huh, C. G., Longenecker, G., Veeranna, Pant, H. C., Brady, R. O., Martin, L. J., & Kulkarni, A. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11173 · Cited by 894
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 855
Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to Mitosis
Gavet, O., & Pines, J. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.02.013 · Cited by 844
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
mTORC1 controls the adaptive transition of quiescent stem cells from G0 to GAlert
Rodgers, J. T., King, K. Y., Brett, J. O., Cromie, M. J., Charville, G. W., Maguire, K. K., Brunson, C., Mastey, N., Liu, L., Tsai, C.-R., et al. (2014) · Nature · doi:10.1038/nature13255 · Cited by 776
Diehl, J. A., Zindy, F., & Sherr, C. J. (1997) · Genes & Development · doi:10.1101/gad.11.8.957 · Cited by 746
Pavletich, N. P. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2640 · Cited by 744
Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis
Sicinski, P., Donaher, J. L., Geng, Y., Parker, S. B., Gardner, H., Park, M. Y., Robker, R. L., Richards, J. S., McGinnis, L. K., Biggers, J. D., et al. (1996) · Nature · doi:10.1038/384470a0 · Cited by 697
Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication
Okuda, M., Horn, H. F., Tarapore, P., Tokuyama, Y., Smulian, A. G., Chan, P.-K., Knudsen, E. S., Hofmann, I. A., Snyder, J. D., Bove, K. E., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00093-3 · Cited by 685
Self-citationCDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 672
Expression and amplification of cyclin genes in human breast cancer.
Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., DeFazio, A., Watts, C. K. W., Musgrove, E. A., & Sutherland, R. L. (1993) · PubMed · Cited by 667
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., Tan, Y., Ackerson, T., & Costa, R. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10875-10894.2005 · Cited by 627
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
The spindle checkpoint, aneuploidy, and cancer
Bharadwaj, R., & Yu, H. (2004) · Oncogene · doi:10.1038/sj.onc.1207374 · Cited by 534
Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
The DREAM complex: master coordinator of cell cycle-dependent gene expression
Sadasivam, S., & DeCaprio, J. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3556 · Cited by 524
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Cyclin D1 protein expression and function in human breast cancer
Bartkova, J., Lukas, J., Müller, H., Lützhøt, D., Strauss, M., & Bartek, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570311 · Cited by 509
Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation.
Xiong, Y., Zhang, H., & Beach, D. (1993) · Genes & Development · doi:10.1101/gad.7.8.1572 · Cited by 507
Cheng, M., Sexl, V., Sherr, C. J., & Roussel, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1091 · Cited by 496
Cycling to Cancer with Cyclin D1
Diehl, J. A. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.72 · Cited by 475
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Monitoring Tumorigenesis and Senescence In Vivo with a p16INK4a-Luciferase Model
Burd, C. E., Sorrentino, J. A., Clark, K. S., Darr, D. B., Krishnamurthy, J., Deal, A. M., Bardeesy, N., Castrillon, D. H., Beach, D. H., & Sharpless, N. E. (2013) · Cell · doi:10.1016/j.cell.2012.12.010 · Cited by 419
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Putting the stress on senescence
Serrano, M., & Blasco, M. A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00278-7 · Cited by 413
Amplification and expression of the human cyclin D gene in esophageal cancer.
Jiang, W. B., Kahn, S. M., Tomita, N., Zhang, Y. J., Lu, S., & Weinstein, I. B. (1992) · PubMed · Cited by 404
Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 403
Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5476 · Cited by 399
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
TFIIH is negatively regulated by cdk8-containing mediator complexes
Akoulitchev, S., Chuikov, S., & Reinberg, D. (2000) · Nature · doi:10.1038/35024111 · Cited by 393
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Self-citationByrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 390
Cyclin E-induced S phase without activation of the pRb/E2F pathway.
Lukas, J., Herzinger, T., Hansen, K., Moroni, M. C., Resnitzky, D., Helin, K., Reed, S. I., & Bartek, J. (1997) · Genes & Development · doi:10.1101/gad.11.11.1479 · Cited by 378
Regulation of the APC and the exit from mitosis
Morgan, D. O. (1999) · Nature Cell Biology · doi:10.1038/10039 · Cited by 373
Ma, T., Van Tine, B. A., Wei, Y., Garrett, M. D., Nelson, D., Adams, P. D., Wang, J., Qin, J., Chow, L. T., & Harper, J. W. (2000) · Genes & Development · doi:10.1101/gad.829500 · Cited by 372
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
Lukas, J., Bartkova, J., Rohde, M., Strauss, M., & Bartek, J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2600 · Cited by 366
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
Self-citationOncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
Polo-like kinases: positive regulators of cell division from start to finish
Nigg, E. A. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80121-x · Cited by 344
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Self-citationThe Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.
Khatib, Z. A., Matsushime, H., Valentine, M. B., Shapiro, D. N., Sherr, C. J., & Look, A. T. (1993) · PubMed · Cited by 338
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
Draetta, G., Brizuela, L., Potashkin, J., & Beach, D. (1987) · Cell · doi:10.1016/0092-8674(87)90227-3 · Cited by 337
Cyclins D2 and D1 Are Essential for Postnatal Pancreatic β-Cell Growth
Kushner, J. A., Ciemerych, M. A., Sicinska, E., Wartschow, L. M., Teta, M., Long, S. Y., Sicinski, P., & White, M. F. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3752-3762.2005 · Cited by 334
Activation of cyclin B1–Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis
Gavet, O., & Pines, J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200909144 · Cited by 334
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
Self-citationE2Fs link the control of G1/S and G2/M transcription
Zhu, W., Giangrande, P. H., & Nevins, J. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600459 · Cited by 320
Michaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression
Sadasivam, S., Duan, S., & DeCaprio, J. A. (2012) · Genes & Development · doi:10.1101/gad.181933.111 · Cited by 309
Herrera, R. E., Sah, V. P., Williams, B. O., Mäkelä, T. P., Weinberg, R. A., & Jacks, T. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.5.2402 · Cited by 304
Thangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302
Self-citationExpression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Konecny, G. E., Winterhoff, B., Kolarova, T., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.-J., Anderson, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2307 · Cited by 302
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
The Molecular Balancing Act of p16INK4a in Cancer and Aging
LaPak, K. M., & Burd, C. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 291
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
Self-citationKouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D., Meyer, R., Lohmann, R., Lopez, P., Powers, J., Turner, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.057 · Cited by 277
Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
Development of mice expressing a single D-type cyclin
Ciemerych, M. A., Kenney, A. M., Sicinska, E., Kalaszczynska, I., Bronson, R. T., Rowitch, D. H., Gardner, H., & Sicinski, P. (2002) · Genes & Development · doi:10.1101/gad.1023602 · Cited by 267
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
The Retinoblastoma Protein Pathway in Cell Cycle Control and Cancer
Bartek, J., Bartkova, J., & Lukas, J. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3776 · Cited by 254
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors
Jeffrey, P. D., Tong, L., & Pavletich, N. P. (2000) · Genes & Development · doi:10.1101/gad.851100 · Cited by 239
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Self-citationSynthetic lethality between CCNE1 amplification and loss of BRCA1
Etemadmoghadam, D., Weir, B. A., Au-Yeung, G., Alsop, K., Mitchell, G., George, J., Australian Ovarian Cancer Study Group, Davis, S., D’Andrea, A. D., Simpson, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314302110 · Cited by 225
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223
The Petinoblastoma Tumor Suppressor Protein
(1994) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60834-9 · Cited by 219
Tong, W.-G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., Harvey, R. D., Badros, A. Z., Popplewell, L., Coutre, S., Fox, J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1347 · Cited by 215
Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression
Knudsen, E. S., Buckmaster, C., Chen, T.-T., Feramisco, J. R., & Wang, J. Y. J. (1998) · Genes & Development · doi:10.1101/gad.12.15.2278 · Cited by 210
Self-citationKarst, A. M., Jones, P. M., Vena, N., Ligon, A. H., Liu, J. F., Hirsch, M. S., Etemadmoghadam, D., Bowtell, D. D. L., & Drapkin, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2247 · Cited by 208
Franco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
Self-citationYoung, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C., Liu, W., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206
Möröy, T., & Geisen, C. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2003.12.005 · Cited by 202
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
Huang, C.-H., Lujambio, A., Zuber, J., Tschaharganeh, D. F., Doran, M. G., Evans, M. J., Kitzing, T., Zhu, N., de Stanchina, E., Sawyers, C. L., et al. (2014) · Genes & Development · doi:10.1101/gad.244368.114 · Cited by 198
Whittaker, S. R., Walton, M. I., Garrett, M. D., & Workman, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0110 · Cited by 195
Requirement for tyrosine phosphorylation of Cdk4 in Gl arrest induced by ultraviolet irradiation
Terada, Y., Tatsuka, M., Jinno, S., & Okayama, H. (1995) · Nature · doi:10.1038/376358a0 · Cited by 186
Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C.
Tassan, J. P., Jaquenoud, M., Léopold, P., Schultz, S. J., & Nigg, E. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8871 · Cited by 184
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
Carozzi, F., Confortini, M., Palma, P. D., Del Mistro, A., Gillio-Tos, A., De Marco, L., Giorgi-Rossi, P., Pontenani, G., Rosso, S., Sani, C., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70208-0 · Cited by 181
Nurse, P., Masui, Y., & Hartwell, L. (1998) · Nature Medicine · doi:10.1038/2594 · Cited by 177
NOBEL LECTURE: Cyclin Dependent Kinases and Cell Cycle Control
Nurse, P. M. (2002) · Bioscience Reports · doi:10.1023/a:1022017701871 · Cited by 173
Finn, R. S., Boer, K., Bondarenko, I., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y. V., Thummala, A., Voitko, N., Bananis, E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05755-7 · Cited by 171
Human cyclin-dependent kinase-activating kinase exists in three distinct complexes.
Drapkin, R., Le Roy, G., Cho, H., Akoulitchev, S., & Reinberg, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6488 · Cited by 166
Mita, M. M., Joy, A. A., Mita, A. C., Sankhala, K. K., Jou, Y., Zhang, D., Statkevich, P., Zhu, Y., Yao, S., Small, K. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.016 · Cited by 166
Le Tourneau, C., Faivre, S., Laurence, V., Delbaldo, C., Vera, K., Girre, V., Chiao, J., Armour, S., Frame, S., Green, S. R., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.08.001 · Cited by 163
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
McClendon, A. K., Dean, J. L., Rivadeneira, D. B., Yu, J. E., Reed, C. A., Gao, E., Farber, J. L., Force, T., Koch, W. J., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21127 · Cited by 163
Self-citationBarton, K. L., Misuraca, K., Cordero, F., Dobrikova, E., Min, H. D., Gromeier, M., Kirsch, D. G., & Becher, O. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077639 · Cited by 162
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
Dean, J. L., McClendon, A. K., & Knudsen, E. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365494 · Cited by 155
Self-citationCyclin-dependent kinase inhibitor therapy for hematologic malignancies
Bose, P., Simmons, G. L., & Grant, S. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.789859 · Cited by 153
Kang, J., Sergio, C. M., Sutherland, R. L., & Musgrove, E. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-32 · Cited by 152
Caldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 151
The Role of Cdk5 in Neuroendocrine Thyroid Cancer
Pozo, K., Castro-Rivera, E., Tan, C., Plattner, F., Schwach, G., Siegl, V., Meyer, D., Guo, A., Gundara, J., Mettlach, G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.027 · Cited by 150
Cell Cycle Progression without Cyclin D-CDK4 and Cyclin D-CDK6 Complexes
Kozar, K., & Siciński, P. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1551 · Cited by 147
Marzec, M., Kasprzycka, M., Lai, R., Gladden, A. B., Wlodarski, P., Tomczak, E., Nowell, P., DePrimo, S. E., Sadis, S., Eck, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016634 · Cited by 146
Cell cycle control and cancer.
Sherr, C. J. (2000) · PubMed · Cited by 145
Draviam, V. M., Orrechia, S., Lowe, M., Pardi, R., & Pines, J. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.5.945 · Cited by 143
Markey, M. P., Angus, S. P., Strobeck, M. W., Williams, S., Gunawardena, R. W., Aronow, B. J., & Knudsen, E. S. (2002) · PubMed · Cited by 140
Self-citationHigh cyclin B1 expression is associated with poor survival in breast cancer
Aaltonen, K., Amini, R., Heikkilä, P., Aittomäki, K., Tamminen, A., Nevanlinna, H. A., & BLOMQVIST, C. P. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604874 · Cited by 134
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status
Kelland, L. R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.12.2903 · Cited by 134
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
A unique function for cyclin D3 in early B cell development
Cooper, A. B., Sawai, C. M., Sicińska, E., Powers, S. E., Siciński, P., Clark, M. R., & Aifantis, I. (2006) · Nature Immunology · doi:10.1038/ni1324 · Cited by 131
Tate, S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., & Cronier, D. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2846 · Cited by 130
Sosman, J. A., Kittaneh, M., Lolkema, M. P. J. K., Postow, M. A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., & Kim, K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9009 · Cited by 129
Nemunaitis, J. J., Small, K. A., Kirschmeier, P., Zhang, D., Zhu, Y., Jou, Y.-M., Statkevich, P., Yao, S.-L., & Bannerji, R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-259 · Cited by 129
Finn, R., Crown, J., Lang, I., Boer, K., Bondarenko, I., Kulyk, S., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s1-6 · Cited by 128
Liu, F., & Korc, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0562 · Cited by 128
Rivadeneira, D. B., Mayhew, C. N., Thangavel, C., Sotillo, E., Reed, C. A., Graña, X., & Knudsen, E. S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.007 · Cited by 125
Self-citationByth, K. F., Thomas, A., Hughes, G., Forder, C., McGregor, A., Geh, C., Oakes, S., Green, C., Walker, M., Newcombe, N., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0836 · Cited by 121
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.24 · Cited by 121
Self-citationNOBEL LECTURE: Yeast and Cancer
Hartwell, L. H. (2002) · Bioscience Reports · doi:10.1023/a:1020918107706 · Cited by 119
Pyrido[2,3- d ]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4
VanderWel, S. N., Harvey, P. J., McNamara, D. J., Repine, J. T., Keller, P. R., Quin, J., Booth, R. J., Elliott, W. L., Dobrusin, E. M., Fry, D. W., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049355+ · Cited by 119
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G.-F., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 116
DePinto, W., Chu, X., Yin, X., Smith, M., Packman, K. E., Goelzer, P., Lovey, A. J., Chen, Y., Qian, H., Hamid, R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0355 · Cited by 116
The two faces of Cdk8, a positive/negative regulator of transcription
Nemet, J., Jelicic, B., Rubelj, I., & Sopta, M. (2014) · Biochimie · doi:10.1016/j.biochi.2013.10.004 · Cited by 115
Heath, E. I., Bible, K. C., Martell, R. E., Adelman, D. C., & LoRusso, P. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9090-3 · Cited by 114
Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114
Targeting cell cycle and hormone receptor pathways in cancer
Comstock, C. E. S., Augello, M. A., Goodwin, J. F., de Leeuw, R., Schiewer, M. J., Ostrander, W. F., Burkhart, R. A., McClendon, A. K., McCue, P. A., Trabulsi, E. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.83 · Cited by 113
Logan, J. E., Mostofizadeh, N., Desai, A. J., von Euw, E., Conklin, D. F., Konkankit, V., Hamidi, H., Eckardt, M. A., Anderson, L. A., Chen, H., et al. (2013) · PubMed · Cited by 111
A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
Menu, E., Garcia, J., Huang, X., Di Liberto, M., Toogood, P. L., Chen, I., Vanderkerken, K., & Chen-Kiang, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6404 · Cited by 107
A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene
Ye, X. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041596198 · Cited by 105
Cell cycle regulation and RNA polymerase II
David, B. B. (2000) · Frontiers in bioscience · doi:10.2741/bregman · Cited by 104
Proliferation: the Most Prominent Predictor of Clinical Outcome in Breast Cancer
Desmedt, C., & Sotiriou, C. P. (2006) · Cell Cycle · doi:10.4161/cc.5.19.3254 · Cited by 103
Stephenson, J., Nemunaitis, J. J., Joy, A. A., Martin, J., Jou, Y., Zhang, D., Statkevich, P., Yao, S., Zhu, Y., Zhou, H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.020 · Cited by 101
Hunt, T., Nasmyth, K., & Novák, B. (2011) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0274 · Cited by 101
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
Walsby, E. J., Pratt, G., Shao, H., Abbas, A. Y., Fischer, P. M., Bradshaw, T. D., Brennan, P., Fegan, C., Wang, S., & Pepper, C. J. (2013) · Oncotarget · doi:10.18632/oncotarget.1568 · Cited by 100
Nigg, E. A., Blangy, A., & Lane, H. A. (1996) · Experimental Cell Research · doi:10.1006/excr.1996.0356 · Cited by 100
Lin, T. S., Blum, K. A., Fischer, D. B., Mitchell, S. M., Ruppert, A. S., Porcu, P., Kraut, E. H., Baiocchi, R. A., Moran, M. E., Johnson, A. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1570 · Cited by 99
Wu, C., Kirley, S. D., Xiao, H., Chuang, Y., Chung, D. C., & Zukerberg, L. R. (2001) · PubMed · Cited by 97
Hartwell, L. H. (2004) · Bioscience Reports · doi:10.1007/s10540-005-2743-6 · Cited by 93
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.211 · Cited by 91
Self-citationDiscovery and Evaluation of Dual CDK1 and CDK2 Inhibitors
Payton, M., Chung, G., Yakowec, P., Wong, A., Powers, D., Xiong, L., Zhang, N., Leal, J., Bush, T. L., Santora, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2507 · Cited by 83
Treatment of growing teratoma syndrome
Vaughn, D. J., Flaherty, K., Lal, P., Gallagher, M., O'Dwyer, P., Wilner, K., Chen, I., & Schwartz, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808558 · Cited by 82
Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins
Yu, Q., Ciemerych, M. A., & Siciński, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208853 · Cited by 80
Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma
Kuhn, E., Bahadirli-Talbott, A., & Shih, I. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.209 · Cited by 79
Emerging drug profile: cyclin-dependent kinase inhibitors
Blachly, J. S., & Byrd, J. C. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.783911 · Cited by 74
Cell cycle regulation and RNA polymerase II
Bregman, D. B. (2000) · Frontiers in bioscience · doi:10.2741/a508 · Cited by 73
Whiteway, S. L., Harris, P. S., Venkataraman, S., Alimova, I., Birks, D. K., Donson, A. M., Foreman, N. K., & Vibhakar, R. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1000-7 · Cited by 68
CDC25A targeting by miR-483-3p decreases CCND–CDK4/6 assembly and contributes to cell cycle arrest
Bertero, T., Gastaldi, C., Bourget, I., Mari, B. P., Meneguzzi, G., Barbry, P., Ponzio, G., & Rezzonico, R. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.5 · Cited by 67
Niméus‐Malmström, E., Koliadi, A., Ahlin, C., Holmqvist, M., Holmberg, L., Amini, R. ‐., Jirström, K., Wärnberg, F., BLOMQVIST, C. P., Fernö, M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.25091 · Cited by 67
NOBEL LECTURE: Protein Synthesis, Proteolysis, and Cell Cycle Transitions
Hunt, T. (2002) · Bioscience Reports · doi:10.1023/a:1022077317801 · Cited by 67
Shapiro, G., Rosen, L. S., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Kulanthaivel, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2500 · Cited by 67
Boss, D. S., Schwartz, G. K., Middleton, M. R., Amakye, D. D., Swaisland, H., Midgley, R. S., Ranson, M., Danson, S. J., Calvert, H., Plummer, R., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp377 · Cited by 66
Sever-Chroneos, Z., Angus, S. P., Fribourg, A. F., Wan, H., Todorov, I., Knudsen, K. E., & Knudsen, E. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4032-4045.2001 · Cited by 64
Self-citationInfante, J. R., Shapiro, G., Witteveen, P., Gerecitano, J. F., Ribrag, V., Chugh, R., Issa, I., Chakraborty, A., Matano, A., Zhao, X., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2528 · Cited by 61
Ismail, A., Bandla, S., Reveiller, M., Toia, L., Zhou, Z., Gooding, W. E., Kalatskaya, I., Stein, L., D'Souza, M., Litle, V. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0244 · Cited by 54
Blum, K. A., Ruppert, A. S., Woyach, J. A., Jones, J. A., Andritsos, L. A., Flynn, J. M., Rovin, B. H., Villalona-Calero, M. A., Ji, J., Phelps, M. A., et al. (2011) · Leukemia · doi:10.1038/leu.2011.109 · Cited by 52
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct101 · Cited by 51
Spangler, L., Wang, X., Conaway, J. W., Conaway, R., & Dvir, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101004498 · Cited by 48
Spofford, L. S., Abel, E. V., Boisvert-Adamo, K., & Aplin, A. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600197200 · Cited by 42
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.534 · Cited by 42
Mahoney, E., Byrd, J. C., & Johnson, A. J. (2013) · Autophagy · doi:10.4161/auto.23027 · Cited by 41
Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
Park, S., Lee, J., Do, I., Jang, J., Rho, K., Ahn, S., Lira, M., Kim, S. J., Kim, K., Mao, M., et al. (2014) · Scientific Reports · doi:10.1038/srep03623 · Cited by 38
Munster, P. N., Hamilton, E. P., Franklin, C., Bhansali, S., Wan, K., Hewes, B., & Juric, D. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.533 · Cited by 33
Therapeutic opportunities to control tumor cell cycles
Malumbres, M. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0193-7 · Cited by 32
Slamon, D., Hurvitz, S. A., Applebaum, S., Glaspy, J. A., Allison, M. K., DiCarlo, B. A., Courtney, R., Kim, S. T., Randolph, S., & Finn, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3060 · Cited by 30
Diab, S., Eckhardt, S. G., Tan, A. R., Frenette, G., Gore, L., DePinto, W., Grippo, J. F., DeMario, M., Mikulski, S. M., & Papadimitrakopoulou, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3528 · Cited by 29
Goldman, J. W., Gandhi, L., Patnaik, A., Rosen, L. S., Hilton, J. F., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8026 · Cited by 27
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Self-citationTreating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Self-citation
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.